Sort by:
- Doctors (8)
Sheraz Daya
Contact Info
Office Hours
- Today
- -
Sheraz Daya
Languages Spoken
- English
- Spanish
- Italian
Certification and Association
- GMC 2983998 Specialist Register, Ophthalmology
- American College of Surgeons Fellow
- American Academy of Ophthalmology Fellow
- American College of Physicians Fellow
- International College of Surgeons Board Member Fellow
- Council Member – United Kingdom & Ireland Society of Refractive and Cataract Surgery (1995 to 2001)
- Council Member – British Society of Cataract & Refractive Surgery (1999 to 2002)
- The Cornea Society, USA (Nov 2003 to date)
- International Society of Refractive Keratoplasty (ISRS)
- Royal College of Ophthalmologists Member
Education
- FRCOphth
- FRCS(Ed)
- FACS
- FACP
- MD
Select Your Region
Latin America
References
1. Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.
2. Martínez-Plaza E, López-Miguel A, López-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226: 117-125.
3. Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six Month Results from the United States Food and Drug Administration Clinical Trial. Clin Ophthalmol. 2022;16:1541-53.
4. Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.
5. Zhang H, Deng Y, Ma K, Yin H, Tang J. Analysis on the changes of objective indicators of dry eye after implantable collamer lens (ICL) implantation surgery. Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2321-2328.
6. Albo C, Nasser T, Szynkarski DT, Nguyen N, Mueller B, Libfraind L, Parkhurst G. A Comprehensive Retrospective Analysis of EVO/EVO+ Implantable Collamer Lens: Evaluating Refractive Outcomes in the Largest Single Center Study of ICL Patients in the United States. Clin Ophthalmol. 2024 Jan 9;18:69-78.